Education
About Us
Working with TipRanks
Follow Us
Prescient Therapeutics Limited (AU:PTX)
ASX:PTX
PTX Stock Chart & Stats
AU$0.08
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.08
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.13
Previous CloseN/A
Volume766.17K
Average Volume (3M)690.15K
Market Cap
AU$67.30M
Enterprise ValueAU$63.54M
Total Cash (Recent Filing)AU$6.93M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Feb 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,051,514,500
10 Day Avg. Volume838,009
30 Day Avg. Volume690,151
Financial Highlights & Ratios
PEG Ratio0.45
Price to Book (P/B)3.11
Price to Sales (P/S)8.13
P/FCF Ratio-4.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthSustained ~44% revenue growth in 2025 indicates improving commercial traction or service uptake, allowing operating leverage as scale increases. Over 2-6 months this trend supports continued investment in R&D and clinical programs and reduces time to potential breakeven if maintained.
Conservative Balance SheetVery low leverage reduces refinancing and interest-rate risk, preserving financial optionality for clinical development. This durable strength gives the company flexibility to raise capital or partner selectively without imminent debt servicing pressure, supporting long-term program execution.
Pipeline Focus (CAR-T & Precision Oncology)A pipeline centered on CAR-T and targeted oncology aligns with structural industry demand for precision and cell therapies, which carry high clinical and commercial barriers to entry. This strategic focus supports meaningful long-term upside via differentiated therapeutics or partnership/licensing pathways.
Bears Say
Persistent LossesOngoing operating losses indicate the business has not yet reached sustainable profitability. Persistently negative results consume equity and limit reinvestment capacity; without clear inflection this structurally raises financing needs and increases execution risk over the medium term.
Negative Free Cash FlowConsistent negative operating and free cash flow, with FCF worsening ~25% in 2025, signals increasing cash burn. This durable cash consumption pattern heightens dependence on external funding, risks dilution or project delays, and constrains strategic optionality if markets tighten.
Eroding Equity / Negative ROEDeclining equity and negative ROE reflect value erosion from cumulative losses. This weakens the capital base, reducing the buffer for clinical setbacks and increasing the urgency of financing or partnerships. Over months this impacts negotiating leverage and long-term resilience.
Prescient Therapeutics Limited News
PTX FAQ
What was Prescient Therapeutics Limited’s price range in the past 12 months?
Prescient Therapeutics Limited lowest share price was AU$0.04 and its highest was AU$0.13 in the past 12 months.
What is Prescient Therapeutics Limited’s market cap?
Prescient Therapeutics Limited’s market cap is AU$67.30M.
When is Prescient Therapeutics Limited’s upcoming earnings report date?
Prescient Therapeutics Limited’s upcoming earnings report date is Feb 20, 2026 which is yesterday.
How were Prescient Therapeutics Limited’s earnings last quarter?
Prescient Therapeutics Limited released its earnings results on Aug 20, 2025. The company reported -AU$0.006 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.006.
Is Prescient Therapeutics Limited overvalued?
According to Wall Street analysts Prescient Therapeutics Limited’s price is currently Overvalued.
Does Prescient Therapeutics Limited pay dividends?
Prescient Therapeutics Limited does not currently pay dividends.
What is Prescient Therapeutics Limited’s EPS estimate?
Prescient Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prescient Therapeutics Limited have?
Prescient Therapeutics Limited has 1,051,514,500 shares outstanding.
What happened to Prescient Therapeutics Limited’s price movement after its last earnings report?
Prescient Therapeutics Limited reported an EPS of -AU$0.006 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.273%.
Which hedge fund is a major shareholder of Prescient Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:PTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prescient Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-4.54%
12-Months-Change
Fundamentals
Return on Equity
-49.72%
Trailing 12-Months
Asset Growth
-28.59%
Trailing 12-Months
Company Description
Prescient Therapeutics Limited
Prescient Therapeutics Limited, a clinical stage oncology company, develops novel drugs for the treatment of various cancers in Australia. Its lead drug candidate is PTX-200, which is in Phase 2a clinical trial for HER2-negative breast cancer, Phase IB/2 clinical trial in relapsed and refractory AML, and Phase 1b in recurrent or persistent platinum-resistant ovarian cancer; and PTX-100, a RhoA inhibitor, for hematological and solid malignancies that focuses on cancers with Ras and RhoA mutations. It has a strategic collaboration with The University of Texas MD Anderson Cancer Center to develop blood cancer binder for OmniCAR. The company was formerly known as Virax Holdings Limited and changed its name to Prescient Therapeutics Limited in December 2014. Prescient Therapeutics Limited was incorporated in 1986 and is based in Melbourne, Australia.
Technical Analysis
Cynata Therapeutics Limited
―
Starpharma Holdings Limited
―
Avecho Biotechnology Limited
―
Chimeric Therapeutics Ltd.
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---